Combined dopamine (D2) and serotonin (5-HT2) receptor antagonist. Prepn: J. K. Perregaard, EP 200322; idem, US 4710500 (1986, 1987 both to Lundbeck); idem et al., J. Med. Chem. 35, 1092 (1992). Neuropharmacology and receptor binding study: C. Sanchez et al., Drug Dev. Res. 22, 239 (1991). Reviews of clinical efficacy and safety: J. M. Kane, Int. Clin. Psychopharmacol. 13, Suppl. 3, S59-S64 (1997); A. S. Hale, ibid. S65-S70.
Antipsychotic.
Antipsychotic; Serotonin-Dopamine Antagonist